Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 19;20(6):1389.
doi: 10.3390/ijms20061389.

Glycans as Biomarkers in Prostate Cancer

Emma Scott  1 , Jennifer Munkley  2
Affiliations
Review

Glycans as Biomarkers in Prostate Cancer

Emma Scott et al. Int J Mol Sci. .

Abstract

Prostate cancer is the most commonly diagnosed malignancy in men, claiming over350,000 lives worldwide annually. Current diagnosis relies on prostate-specific antigen (PSA)testing, but this misses some aggressive tumours, and leads to the overtreatment of non-harmfuldisease. Hence, there is an urgent unmet clinical need to identify new diagnostic and prognosticbiomarkers. As prostate cancer is a heterogeneous and multifocal disease, it is likely that multiplebiomarkers will be needed to guide clinical decisions. Fluid-based biomarkers would be ideal, andattention is now turning to minimally invasive liquid biopsies, which enable the analysis oftumour components in patient blood or urine. Effective diagnostics using liquid biopsies willrequire a multifaceted approach, and a recent high-profile review discussed combining multipleanalytes, including changes to the tumour transcriptome, epigenome, proteome, and metabolome.However, the concentration on genomics-based paramaters for analysing liquid biopsies ispotentially missing a goldmine. Glycans have shown huge promise as disease biomarkers, anddata suggests that integrating biomarkers across multi-omic platforms (including changes to theglycome) can improve the stratification of patients with prostate cancer. A wide range ofalterations to glycans have been observed in prostate cancer, including changes to PSAglycosylation, increased sialylation and core fucosylation, increased O-GlcNacylation, theemergence of cryptic and branched N-glyans, and changes to galectins and proteoglycans. In thisreview, we discuss the huge potential to exploit glycans as diagnostic and prognostic biomarkersfor prostate cancer, and argue that the inclusion of glycans in a multi-analyte liquid biopsy test forprostate cancer will help maximise clinical utility.

Keywords: biomarkers; glycans; glycosylation; liquid biopsy; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Glycans, the understudied major building blocks of life. The glycoproteome combines three highly adaptable interdependent biological alphabets. Created with BioRender.
Figure 2
Figure 2
The importance of glycans can be conceptualised as an extended model of the central dogma. Created with BioRender.
See this image and copyright information in PMC

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016;66:7–30. doi: 10.3322/caac.21332. - DOI - PubMed
    1. Attard G., Parker C., Eeles R.A., Schroder F., Tomlins S.A., Tannock I., Drake C.G., de Bono J.S. Prostate cancer. Lancet. 2016;387:70–82. doi: 10.1016/S0140-6736(14)61947-4. - DOI - PubMed
    1. Jamaspishvili T., Kral M., Khomeriki I., Student V., Kolar Z., Bouchal J. Urine markers in monitoring for prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:12–19. doi: 10.1038/pcan.2009.31. - DOI - PubMed
    1. Drake R.R., White K.Y., Fuller T.W., Igwe E., Clements M.A., Nyalwidhe J.O., Given R.W., Lance R.S., Semmes O.J. Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. J. Proteom. 2009;72:907–917. doi: 10.1016/j.jprot.2009.01.007. - DOI - PMC - PubMed
    1. Crowley E., Di Nicolantonio F., Loupakis F., Bardelli A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 2013;10:472–484. doi: 10.1038/nrclinonc.2013.110. - DOI - PubMed